Cordance Medical Raises $8 Million Seed Round to Advance Noninvasive Focused Ultrasound Platform for Brain Disease Treatment
Cordance Medical, a medical technology company developing a noninvasive focused ultrasound platform designed to safely and temporarily open the blood–brain barrier (BBB), has secured new funding to advance its technology into first-in-human clinical trials. In November 2025, the company announced the close of an oversubscribed $8 million seed financing round, exceeding its original fundraising target and signaling strong investor confidence in its approach to addressing neurological and brain cancer treatment challenges.
The seed round was led by Sonder Capital, a venture firm focused on transformative healthcare technologies. Additional investors participating in the financing included Shanda Grab Ventures, Angel Physician’s Fund, SmartGateVC, and R42. The round also drew support from mission-driven and disease-focused investment groups, including the Sontag Foundation Innovation Fund and the Brain Tumor Investment Fund, a portfolio entity of the National Brain Tumor Society. Together, the diverse investor base reflects broad support from both traditional venture capital and organizations dedicated to advancing therapies for neurological diseases.
Cordance Medical is focused on overcoming one of the most persistent challenges in neurology and neuro-oncology: delivering therapeutic agents across the blood–brain barrier. The company’s NeuroAccess™ platform uses focused ultrasound combined with proprietary signal processing to enable controlled, reversible BBB opening without the need for invasive procedures. The system is designed to function without rigid head fixation or continuous imaging during treatment, potentially enabling more accessible and scalable outpatient use.
Proceeds from the seed financing will primarily be used to support Cordance Medical’s first-in-human clinical trial, a critical milestone as the company transitions from preclinical development to clinical validation. The NeuroAccess™ platform has already received FDA Breakthrough Device Designation for neuro-oncology applications, a designation intended to accelerate the development and review of medical devices that address unmet medical needs.
According to the company’s leadership, the oversubscribed round provides both the capital and strategic backing necessary to move efficiently toward clinical testing. Co-founder and CEO Bhaskar Ramamurthy, Ph.D., has emphasized that the financing strengthens Cordance Medical’s ability to demonstrate the safety and effectiveness of its technology while expanding awareness among clinicians and potential partners.
Investors have pointed to the platform’s potential to redefine how drugs are delivered to the brain. By enabling temporary and targeted BBB opening, Cordance Medical’s technology could enhance the effectiveness of existing and emerging therapies for brain tumors and other neurological conditions, where drug delivery limitations have historically constrained treatment outcomes.
In addition to its therapeutic focus, Cordance Medical is also exploring diagnostic applications of focused ultrasound technology. The company has conducted research into ultrasound-enabled liquid biopsy approaches that could allow for less invasive monitoring of brain tumors. These parallel efforts underscore a broader strategy to apply its platform across multiple clinical use cases within neurology and neuro-oncology.
Founded by experts in ultrasound physics, neurotechnology, and medical device development, Cordance Medical is positioning itself at the intersection of engineering innovation and clinical need. The company’s approach aligns with a growing trend toward noninvasive technologies that improve patient comfort while expanding treatment options for complex diseases.
With fresh capital in hand and clinical trials on the horizon, Cordance Medical is entering a pivotal phase of growth. Backed by a mix of venture capital firms and disease-focused investors, the company aims to advance its NeuroAccess™ platform toward regulatory approval and, ultimately, broader clinical adoption. If successful, Cordance Medical’s technology could play a meaningful role in improving outcomes for patients with brain cancer and other neurological disorders by enabling more effective delivery of life-saving therapies.
